Extended Mycophenolate Mofetil and Shortened Cyclosporine Failed to Reduce Graft-versus-Host Disease after Unrelated Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning

Biology of Blood and Marrow Transplantation

Volumn 13, Issue 9, 2007, Pages 1041-1048

  Baron, Frédéric ^a   Sandmaier, Brenda M ^b,c   Storer, Barry E ^b,c   Maris, Michael B ^d   Langston, Amelia A ^e   Lange, Thoralf ^f   Petersdorf, Effie ^b,c   Bethge, Wolfgang ^g   Maziarz, Richard T ^h   McSweeney, Peter A ^d   Pulsipher, Michael A ⁱ   Wade, James C ^j   Chauncey, Thomas R ^b,c,k   Shizuru, Judith A ^l   Sorror, Mohamed L ^b   Woolfrey, Ann E ^b,c   Maloney, David G ^b,c   Storb, Rainer ^b,c  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d Rocky Mountain Blood and Marrow Transplant Program   (United States)

^e EMORY UNIVERSITY   (United States)

^f UNIVERSITY OF LEIPZIG   (Germany)

^g UNIVERSITY OF TÜBINGEN   (Germany)

^h OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

ⁱ UNIVERSITY OF UTAH   (United States)

^j MEDICAL COLLEGE OF WISCONSIN   (United States)

^k VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^l STANFORD UNIVERSITY   (United States)

more..

Author keywords

Cyclosporine; Graft versus host disease; Mycophenolate mofetil; Unrelated hematopoietic cell transplantation

Indexed keywords

ANTIBIOTIC AGENT; CYCLOSPORIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOSTATIN; PREDNISOLONE;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; AGED; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; BLOOD DONOR; CANCER MORTALITY; CANCER RELAPSE; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HLA MATCHING; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NONMYELOABLATIVE CONDITIONING; PNEUMOCYSTOSIS; SHORT COURSE THERAPY; STREPTOCOCCUS INFECTION; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOSPORINE; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; TRANSPLANTATION CONDITIONING; TREATMENT FAILURE;

EID: 34547652742     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2007.05.011     Document Type: Article

References (38)

1. Hallemeier C., Girgis M., Blum W., et al. Outcomes of adults with acute myelogenous leukemia in remission given 550 cGy of single-exposure total body irradiation, cyclophosphamide, and unrelated donor bone marrow transplants. Biol Blood Marrow Transplant 10 (2004) 310-319
2. Wong R., Giralt S.A., Martin T., et al. Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood 102 (2003) 3052-3059
3. Nagler A., Aker M., Or R., et al. Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation. Exp Hematol 29 (2001) 362-370
4. Chakraverty R., Peggs K., Chopra R., et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantion by using a nonmyeloablative conditioning regimen. Blood 99 (2002) 1071-1078
5. Maris M.B., Niederwieser D., Sandmaier B.M., et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood 102 (2003) 2021-2030
6. Giralt S., Estey E., Albitar M., et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 89 (1997) 4531-4536
7. Slavin S., Nagler A., Naparstek E., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91 (1998) 756-763
8. McSweeney P.A., Niederwieser D., Shizuru J.A., et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97 (2001) 3390-3400
9. Baron F., Maris M.B., Sandmaier B.M., et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 23 (2005) 1993-2003
10. Storb R., Yu C., Wagner J.L., et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 89 (1997) 3048-3054
11. Niederwieser D., Maris M., Shizuru J.A., et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 101 (2003) 1620-1629
12. Baron F., Maris M.B., Storer B.E., et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia. Biol Blood Marrow Transplant 11 (2005) 272-279
13. + cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation. Leukemia 19 (2005) 822-828
14. Maris M.B., Sandmaier B.M., Storer B.E., et al. Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing. Biol Blood Marrow Transplant 12 (2006) 454-465
15. Shi Y., Sahai B.M., and Green D.R. Cyclosporin A inhibits activation-induced cell death in T-cell hybridomas and thymocytes. Nature 339 (1989) 625-626
16. Kirk A.D., Burkly L.C., Batty D.S., et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 5 (1999) 686-693
17. Li Y., Li X.C., Zheng X.X., Wells A.D., Turka L.A., and Strom T.B. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 5 (1999) 1298-1302
18. Blaha P., Bigenzahn S., Koporc Z., et al. The influence of immunosuppressive drugs on tolerance induction through bone marrow transplantation with costimulation blockade. [Erratum: Blood. 2003;102:1950]. Blood 101 (2003) 2886-2893
19. Chapuis A.G., Paolo R.G., D'Agostino C., et al. Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo. Nat Med 6 (2000) 762-768
20. Izeradjene K., and Revillard J.P. Apoptosis of superantigen-activated T cells induced by mycophenolate mofetil treatment. Transplantation 71 (2001) 118-125
21. Sullivan K.M. Graft-vs.-host disease. In: Blume K.G., Forman S.J., and Appelbaum F.R. (Eds). Thomas' Hematopoietic Cell Transplantation (2004), Blackwell Publishing Ltd, Oxford, UK 635-664
22. Koc S., Leisenring W., Flowers M.E.D., et al. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood 100 (2002) 48-51
23. Junghanss C., Marr K.A., Carter R.A., et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant 8 (2002) 512-520
24. Sandmaier B.M., Maloney D.G., Maris M.B., et al. Conversion of low donor chimerism following nonmyeloablative conditioning for hematopoietic cell transplantation (HCT) using pentostatin and donor lymphocyte infusion (DLI). Blood 104 (2004) 57a
25. Baron F., Baker J.E., Storb R., et al. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 104 (2004) 2254-2262
26. Baron F., and Sandmaier B.M. Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Leukemia 20 (2006) 1690-1700 (review)
27. Sorror M.L., Maris M.B., Storb R., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106 (2005) 2912-2919
28. Baron F., and Sandmaier B.M. Current status of hematopoietic stem cell transplantation after nonmyeloablative conditioning. Curr Opin Hematol 12 (2005) 435-443
29. Burroughs L., Mielcarek M., Leisenring W., et al. Extending postgrafting cyclosporine decreases the risk of severe graft-versus-host disease after nonmyeloablative hematopoietic cell transplantation. Transplantation 81 (2006) 818-825
30. de Lima M., Anagnostopoulos A., Munsell M., et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 104 (2004) 865-872
31. Crawley C., Lalancette M., Szydlo R., et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 105 (2005) 4532-4539
32. Baron F., Storb R., Storer B.E., et al. Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopietic cell transplantation. J Clin Oncol 24 (2006) 4150-4157
33. Mielcarek M., Martin P.J., Leisenring W., et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 102 (2003) 756-762
34. Mielcarek M., Burroughs L., Leisenring W., et al. Prognostic relevance of "early-onset" graft-versus-host disease following nonmyeloablative hematopoietic cell transplantation. Br J Haematol 129 (2005) 381-391
35. + T-cell dose. Blood 105 (2005) 2300-2306
36. Blaise D.P., Boiron J.M., Faucher C., et al. Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment. Cancer 104 (2005) 1931-1938
37. Bornhauser M., Thiede C., Platzbecker U., et al. Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients. Clin Cancer Res 7 (2001) 2254-2262
38. Kansu E., Gooley T., Flowers M.E.D., et al. Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trial. Blood 98 (2001) 3868-3870 (brief report)